文献速递乳腺癌

乌替地隆联合卡培他滨对比卡培他滨单药治疗蒽环类和紫杉类耐药的经重度治疗的转移性乳腺癌:多中心、开放标签、优效性、3期随机对照试验

Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.
PubMed 文献 · Lancet Oncol · 2017-02-11

这项在中国26家医院进行的多中心、开放标签、优效性3期随机对照试验,纳入270例对蒽环类和紫杉类耐药的转移性乳腺癌患者,按2:1随机接受乌替地隆联合卡培他滨或卡培他滨单药治疗。联合组中位无进展生存期为8.44个月(95%CI 7.95-9.92),单药组为4.27个月(95%CI 3.22-5.68),风险比0.46(95%CI 0.36-0.59;P<0.0001)。

要点

  • 联合组中位无进展生存期8.44个月,单药组4.27个月,风险比0.46(95%CI 0.36-0.59;P<0.0001)。
  • 联合组3级周围神经病变发生58例(22%),单药组1例(<1%)。
  • 研究结果支持乌替地隆联合卡培他滨作为转移性乳腺癌的有效选择。

核心结论

  • 尽管既往化疗后出现疾病进展,乌替地隆联合卡培他滨在无进展生存期结局上比卡培他滨单药更有效,毒性轻微,但周围感觉神经病变除外,该不良反应可控。
  • 研究结果支持乌替地隆联合卡培他滨作为转移性乳腺癌患者的有效选择。

研究设计与样本

  • 多中心、开放标签、优效性、3期随机对照试验,在中国26家医院进行。
  • 纳入对蒽环类和紫杉类化疗方案耐药的女性转移性乳腺癌患者,按2:1随机分配(计算机随机化,区组大小6)。
  • 联合组:乌替地隆30 mg/m2静脉注射每日一次第1-5天,联合卡培他滨1000 mg/m2口服每日两次第1-14天,21天为一周期;单药组:卡培他滨1250 mg/m2口服每日两次第1-14天。
  • 主要终点为独立影像学评审委员会集中评估的无进展生存期,在意向治疗人群中采用Kaplan-Meier乘积极限法分析。
  • 共纳入270例联合组和135例单药组患者;安全性在所有至少接受一剂研究药物的参与者中评估。随访仍在进行中。

主要发现

  • 联合组中位无进展生存期(中心评审)为8.44个月(95%CI 7.95-9.92),单药组为4.27个月(95%CI 3.22-5.68),风险比0.46(95%CI 0.36-0.59;P<0.0001)。
  • 联合组中位无进展生存期随访时间为6.77个月(IQR 3.81-10.32),单药组为4.55个月(IQR 2.55-9.39)。
  • 联合组3级周围神经病变58例(22%,58/267),单药组1例(<1%,1/130)。
  • 单药组3级手掌-足底红斑感觉异常10例(8%,10/130),联合组18例(7%,18/267)。
  • 联合组报告16例严重不良事件(腹泻最常见,3例1%),单药组报告14例严重不良事件(腹泻、血胆红素升高和贫血最常见,各2例2%)。

临床怎么用

  • 研究结果支持乌替地隆联合卡培他滨作为转移性乳腺癌患者的有效选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus capecitabine alone in patients with metastatic breast cancer. METHODS: We did a multicentre, open-label, superiority, phase 3, randomised controlled trial in 26 hospitals in China. Eligible participants were female patients with metastatic breast cancer refractory to anthracycline and taxane chemotherapy regimens. We randomly assigned participants (2:1) using computer based randomisation and block sizes of 6 to a 21-day cycle of either utidelone (30 mg/m2 intravenously once per day on days 1-5) plus capecitabine (1000 mg/m2 orally twice per day on days 1-14), or capecitabine alone (1250 mg/m2 orally twice per day on days 1-14), until disease progression or unacceptable toxicity occurred. Patients, physicians, and assessors were not masked to treatment allocation; however, an independent radiology review committee used to additionally assess response was masked to allocation. The primary endpoint was centrally assessed (by an independent radiology review committee) progression-free survival, and analysed using the Kaplan-Meier product-limit method in the intention-to-treat population. Safety was assessed in all participants who received at least one dose of study drug. Follow-up is ongoing. This study is registered at ClinicalTrials.gov, number NCT02253459. FINDINGS: Between Aug 8, 2014, and Dec 14, 2015, we enrolled and randomly assigned 270 patients to treatment with utidelone plus capecitabine, and 135 to capecitabine alone. Median follow-up for progression-free survival was 6·77 months (IQR 3·81-10·32) for the utidelone plus capecitabine group and 4·55 months (2·55-9·39) for the capecitabine alone group. Median progression-free survival by central review in the utidelone plus capecitabine group was 8·44 months (95% CI 7·95-9·92) compared with 4·27 months (3·22-5·68) in the capecitabine alone group; hazard ratio 0·46, 95% CI 0·36-0·59; p<0·0001. Peripheral neuropathy was the most common grade 3 adverse event in the utidelone plus capecitabine group (58 [22%] of 267 patients vs 1 [<1%] of 130 patients in the capecitabine alone group). Palmar-plantar erythrodysaesthesia was the most prominent grade 3 adverse event in the capacitabine alone group (in 10 [8%] of 130 patients) and was the next most frequent grade 3 event in the utidelone plus capecitabine group (in 18 [7%] of 267 patients). 16 serious adverse events were reported in the combination therapy group (diarrhoea was the most common, in three [1%] patients) and 14 serious adverse events were reported in the monotherapy group (the most common were diarrhoea, increased blood bilirubin, and anaemia, in two [2%] patients for each event). 155 patients died (99 in the combination therapy arm, 56 in the monotherapy arm). All deaths were related to disease progression except for one in each group (attributed to pericardial effusion in the combination therapy group and dyspnoea in the monotherapy group) that were considered possibly or probably treatment-related. INTERPRETATION: Despite disease progression with previous chemotherapies, utidelone plus capecitabine was more efficacious compared with capecitabine alone for the outcome of progression-free survival, with mild toxicity except for peripheral sensory neuropathy, which was manageable. The findings from this study support the use of utidelone plus capecitabine as an effective option for patients with metastatic breast cancer. FUNDING: Beijing Biostar Technologies, Beijing, China.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncol. 2017. PMID: 28209298. doi:10.1016/S1470-2045(17)30088-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。